Albert Labs International (FRA:VB50) Long-Term Debt: €0.01 Mil (As of Sep. 2023)


What is Albert Labs International Long-Term Debt?

Albert Labs International FRA:VB50 Long-Term Debt is €0.01 Mil as of Sep. 2023.

Albert Labs International's Long-Term Debt for the quarter that ended in Sep. 2023 was €0.01 Mil.

Albert Labs International's quarterly Long-Term Debt stayed the same from Mar. 2023 (€0.00 Mil) to Jun. 2023 (€0.00 Mil) but then increased from Jun. 2023 (€0.00 Mil) to Sep. 2023 (€0.01 Mil).

Albert Labs International  (FRA:VB50) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Albert Labs International Long-Term Debt Related Terms

Albert Labs International Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Albert Labs International's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albert Labs International Long-Term Debt Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
Long-Term Debt
0.00 0.00

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.01
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €0.01 Mil mean?
Albert Labs International (FRA:VB50) has a Long-Term Debt of €0.01 Mil as of Sep. 2023.
Is Albert Labs International's Long-Term Debt too high?
Albert Labs International's current Long-Term Debt is €0.01 Mil.
How does Albert Labs International's Long-Term Debt compare to VRTX and REGN?
Albert Labs International's Long-Term Debt of €0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Albert Labs International's current Long-Term Debt is €0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert Labs International stock overvalued right now?
Albert Labs International (FRA:VB50) has a current Long-Term Debt of €0.01 Mil. The current Long-Term Debt is €0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Albert Labs International (FRA:VB50), the current Long-Term Debt is €0.01 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Albert Labs International Business Description

Address 201-6996 Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research, and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of a clinical pathway.